Alvotech announced on February 2 2026 that it has entered into supply and commercialization agreements with Sandoz for a portfolio of biosimilar candidates in Canada, Australia and New Zealand. The Canadian deal covers one ophthalmology biosimilar that will be supplied as a pre‑filled syringe for intravitreal injection, while the Australasian agreement includes three candidates spanning immunology and gastroenterology in multiple formulations.
Under the agreements, Sandoz will lead all regulatory filings and commercial activities in the respective territories, working closely with Alvotech to navigate local approval pathways. Alvotech will retain responsibility for development, global clinical activities and manufacturing, and will supply finished product to Sandoz under exclusive supply arrangements. The financial terms of the deals—including milestone payments, royalties and supply fees—were not disclosed.
Strategically, the partnership expands Alvotech’s commercial footprint in high‑growth markets and leverages Sandoz’s established distribution network. By partnering with a regional player, Alvotech can accelerate market entry and broaden patient access without building its own sales infrastructure in each country, a core element of its global commercialization strategy.
The agreements carry execution risk tied to regulatory approvals and the timing of commercial launches. While the immediate financial impact is limited to future supply fees and royalties, the deals position Alvotech for long‑term revenue growth once the biosimilars receive approval and enter the market.
Chairman Róbert Wessman said the agreements “further advance Alvotech’s strategy of securing commercial pathways for its biosimilar portfolio across global markets ahead of regulatory approval” and highlighted the company’s “integrated development and manufacturing platform” and its focus on “capital discipline.”
Alvotech’s stock has been trading well below its 52‑week high, and analysts have issued neutral to hold ratings, reflecting the company’s ongoing financial challenges and regulatory uncertainties. The new partnerships, however, signal confidence in Alvotech’s pipeline and its ability to partner effectively with established players to bring products to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.